{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T07:18:26Z","timestamp":1790493506962,"version":"4.1.0"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2017,6,9]],"date-time":"2017-06-09T00:00:00Z","timestamp":1496966400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2017,6,9]],"date-time":"2017-06-09T00:00:00Z","timestamp":1496966400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Cyclin D1, a G1-S phase regulator, is upregulated in parathyroid adenomas. Since cyclin-dependent kinase (CDK) inhibitors, CDKN2A and CDKN2B, and RASSF1A (Ras-association domain family 1, isoform A) are involved in G1-S phase arrest and act as potential tumor suppressor genes, we aimed to study potential methylation-mediated inactivation of these genes in parathyroid adenomas. Gene expressions of cyclin D1 (CCND1) and regulatory molecules (CDKN2A, CDKN2B and RASSF1A) was analysed in parathyroid adenoma tissues (n\u2009=\u200930). DNA promoter methylation of cyclin D1 regulators were assessed and correlated with clinicopathological features of the patients. Gene expression analysis showed a relative fold reductions of 0.35 for CDKN2A (p\u2009=\u20090.01), 0.45 for CDKN2B (P\u2009=\u20090.02), and 0.39 for RASSF1A (p\u2009&lt;\u20090.01) in adenomatous compared to normal parathyroid tissue. There was an inverse relationship between the expressions of CDKN2A and CDKN2B with CCND1. In addition, the promoter regions of CDKN2A, CDKN2B, and of RASSF1A were significantly hyper-methylated in 50% (n\u2009=\u200915), 47% (n\u2009=\u200914), and 90% (n\u2009=\u200927) of adenomas respectively. In contrast, no such aberrant methylation of these genes was observed in normal parathyroid tissue. So, promoter hypermethylation is associated with down-regulation of CCND1 regulatory genes in sporadic parathyroid adenomas. This dysregulated cell cycle mechanism may contribute to parathyroid tumorigenesis.<\/jats:p>","DOI":"10.1038\/s41598-017-03143-8","type":"journal-article","created":{"date-parts":[[2017,6,5]],"date-time":"2017-06-05T08:23:15Z","timestamp":1496650995000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":42,"title":["Promoter hypermethylation inactivates CDKN2A, CDKN2B and RASSF1A genes in sporadic parathyroid adenomas"],"prefix":"10.1038","volume":"7","author":[{"given":"Ashutosh Kumar","family":"Arya","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanjay Kumar","family":"Bhadada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Priyanka","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naresh","family":"Sachdeva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Uma Nahar","family":"Saikia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Divya","family":"Dahiya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arunanshu","family":"Behera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anil","family":"Bhansali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sudhaker D.","family":"Rao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,6,9]]},"reference":[{"key":"3143_CR1","unstructured":"Brown, E. M. In Principles and practice of endocrinology and metabolism (ed Kenneth, L. Becker) 478\u2013489 (Lippincott Williams & Wilkins Co., 2001)."},{"key":"3143_CR2","first-page":"412","volume":"12","author":"MA Vasef","year":"1999","unstructured":"Vasef, M. A., Brynes, R. K., Sturm, M., Bromley, C. & Robinson, R. A. Expression of cyclin D1 in parathyroid carcinomas, adenomas, and hyperplasias: a paraffin immunohistochemical study. Mod Pathol \n                           12, 412\u2013416 (1999).","journal-title":"Mod Pathol"},{"key":"3143_CR3","first-page":"449","volume":"6","author":"CL Rosenberg","year":"1991","unstructured":"Rosenberg, C. L., Kim, H. G., Shows, T. B., Kronenberg, H. M. & Arnold, A. Rearrangement and overexpression of D11S287E, a candidate oncogene on chromosome 11q13 in benign parathyroid tumors. Oncogene \n                           6, 449\u2013453 (1991).","journal-title":"Oncogene"},{"key":"3143_CR4","first-page":"1736","volume":"81","author":"ED Hsi","year":"1996","unstructured":"Hsi, E. D., Zukerberg, L. R., Yang, W. I. & Arnold, A. Cyclin D1\/PRAD1 expression in parathyroid adenomas: an immunohistochemical study. J Clin Endocrinol Metab \n                           81, 1736\u20131739 (1996).","journal-title":"J Clin Endocrinol Metab"},{"key":"3143_CR5","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1530\/EJE-13-0085","volume":"169","author":"S Varshney","year":"2013","unstructured":"Varshney, S. et al. Simultaneous expression analysis of vitamin D receptor, calcium-sensing receptor, cyclin D1, and PTH in symptomatic primary hyperparathyroidism in Asian Indians. Eur J Endocrinol \n                           169, 109\u2013116 (2013).","journal-title":"Eur J Endocrinol"},{"key":"3143_CR6","doi-asserted-by":"publisher","first-page":"1093","DOI":"10.1172\/JCI10523","volume":"107","author":"Y Imanishi","year":"2001","unstructured":"Imanishi, Y. et al. Primary hyperparathyroidism caused by parathyroid-targeted overexpression of cyclin D1 in transgenic mice. J Clin Invest \n                           107, 1093\u20131102 (2001).","journal-title":"J Clin Invest"},{"key":"3143_CR7","doi-asserted-by":"crossref","unstructured":"Rao, S. D., Bhadada, S. K. & Parfitt, A. M. In The Parathyroids (Third Edition) (eds J. P. Bilezikian et al.) 255\u2013278 (Academic Press, 2015).","DOI":"10.1016\/B978-0-12-397166-1.00017-5"},{"key":"3143_CR8","doi-asserted-by":"publisher","first-page":"704","DOI":"10.1038\/366704a0","volume":"366","author":"M Serrano","year":"1993","unstructured":"Serrano, M., Hannon, G. J. & Beach, D. A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D\/CDK4. Nature \n                           366, 704\u2013707 (1993).","journal-title":"Nature"},{"key":"3143_CR9","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1016\/0092-8674(94)90543-6","volume":"79","author":"T Hunter","year":"1994","unstructured":"Hunter, T. & Pines, J. Cyclins and cancer. II: Cyclin D and CDK inhibitors come of age. Cell \n                           79, 573\u2013582 (1994).","journal-title":"Cell"},{"key":"3143_CR10","doi-asserted-by":"publisher","first-page":"1245","DOI":"10.1038\/nm1295-1245","volume":"1","author":"M Strauss","year":"1995","unstructured":"Strauss, M., Lukas, J. & Bartek, J. Unrestricted cell cycling and cancer. Nat Med \n                           1, 1245\u20131246 (1995).","journal-title":"Nat Med"},{"key":"3143_CR11","first-page":"3663","volume":"81","author":"H Tahara","year":"1996","unstructured":"Tahara, H., Smith, A. P., Gaz, R. D. & Arnold, A. Loss of chromosome arm 9p DNA and analysis of the p16 and p15 cyclin-dependent kinase inhibitor genes in human parathyroid adenomas. J Clin Endocrinol Metab \n                           81, 3663\u20133667 (1996).","journal-title":"J Clin Endocrinol Metab"},{"key":"3143_CR12","doi-asserted-by":"publisher","first-page":"e9472","DOI":"10.1371\/journal.pone.0009472","volume":"5","author":"CC Juhlin","year":"2010","unstructured":"Juhlin, C. C. et al. Frequent promoter hypermethylation of the APC and RASSF1A tumour suppressors in parathyroid tumours. PLoS One \n                           5, e9472 (2010).","journal-title":"PLoS One"},{"key":"3143_CR13","doi-asserted-by":"publisher","first-page":"646","DOI":"10.4161\/epi.24823","volume":"8","author":"L Sulaiman","year":"2013","unstructured":"Sulaiman, L. et al. Global and gene-specific promoter methylation analysis in primary hyperparathyroidism. Epigenetics \n                           8, 646\u2013655 (2013).","journal-title":"Epigenetics"},{"key":"3143_CR14","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1002\/gcc.20895","volume":"50","author":"LF Starker","year":"2011","unstructured":"Starker, L. F. et al. The DNA methylome of benign and malignant parathyroid tumors. Genes Chromosomes Cancer \n                           50, 735\u2013745 (2011).","journal-title":"Genes Chromosomes Cancer"},{"key":"3143_CR15","doi-asserted-by":"publisher","first-page":"E1631","DOI":"10.1210\/jc.2013-1699","volume":"98","author":"S Varshney","year":"2013","unstructured":"Varshney, S. et al. Methylation status of the CpG islands in vitamin D and calcium-sensing receptor gene promoters does not explain the reduced gene expressions in parathyroid adenomas. J Clin Endocrinol Metab \n                           98, E1631\u20131635 (2013).","journal-title":"J Clin Endocrinol Metab"},{"key":"3143_CR16","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1186\/1476-4598-9-294","volume":"9","author":"J Svedlund","year":"2010","unstructured":"Svedlund, J. et al. Aberrant WNT\/beta-catenin signaling in parathyroid carcinoma. Mol Cancer \n                           9, 294 (2010).","journal-title":"Mol Cancer"},{"key":"3143_CR17","doi-asserted-by":"crossref","unstructured":"Carling, T., Du, Y., Fang, W., Correa, P. & Huang, S. Intragenic allelic loss and promoter hypermethylation of the RIZ1 tumor suppressor gene in parathyroid tumors and pheochromocytomas. Surgery \n                           134, 932\u2013939, discussion 939\u2013940 (2003).","DOI":"10.1016\/S0039-6060(03)00422-7"},{"key":"3143_CR18","doi-asserted-by":"publisher","first-page":"686","DOI":"10.1038\/nm0795-686","volume":"1","author":"A Merlo","year":"1995","unstructured":"Merlo, A. et al. 5\u2032 CpG island methylation is associated with transcriptional silencing of the tumour suppressor p16\/CDKN2\/MTS1 in human cancers. Nat Med \n                           1, 686\u2013692 (1995).","journal-title":"Nat Med"},{"key":"3143_CR19","first-page":"4525","volume":"55","author":"JG Herman","year":"1995","unstructured":"Herman, J. G. et al. Inactivation of the CDKN2\/p16\/MTS1 gene is frequently associated with aberrant DNA methylation in all common human cancers. Cancer Res \n                           55, 4525\u20134530 (1995).","journal-title":"Cancer Res"},{"key":"3143_CR20","doi-asserted-by":"publisher","first-page":"4309","DOI":"10.1128\/MCB.22.12.4309-4318.2002","volume":"22","author":"L Shivakumar","year":"2002","unstructured":"Shivakumar, L., Minna, J., Sakamaki, T., Pestell, R. & White, M. A. The RASSF1A tumor suppressor blocks cell cycle progression and inhibits cyclin D1 accumulation. Mol Cell Biol \n                           22, 4309\u20134318 (2002).","journal-title":"Mol Cell Biol"},{"key":"3143_CR21","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1634\/theoncologist.2009-0185","volume":"15","author":"M Abdelgadir Adam","year":"2010","unstructured":"Abdelgadir Adam, M., Untch, B. R. & Olson, J. A. Jr. Parathyroid carcinoma: current understanding and new insights into gene expression and intraoperative parathyroid hormone kinetics. Oncologist \n                           15, 61\u201372 (2010).","journal-title":"Oncologist"},{"key":"3143_CR22","doi-asserted-by":"publisher","first-page":"1080","DOI":"10.1002\/ijc.25432","volume":"128","author":"K Shima","year":"2011","unstructured":"Shima, K. et al. Prognostic significance of CDKN2A (p16) promoter methylation and loss of expression in 902 colorectal cancers: Cohort study and literature review. Int J Cancer \n                           128, 1080\u20131094 (2011).","journal-title":"Int J Cancer"},{"key":"3143_CR23","first-page":"1043","volume":"60","author":"K Nosaka","year":"2000","unstructured":"Nosaka, K. et al. Increasing methylation of the CDKN2A gene is associated with the progression of adult T-cell leukemia. Cancer Res \n                           60, 1043\u20131048 (2000).","journal-title":"Cancer Res"},{"key":"3143_CR24","doi-asserted-by":"publisher","first-page":"3163","DOI":"10.1242\/jcs.010389","volume":"120","author":"H Donninger","year":"2007","unstructured":"Donninger, H., Vos, M. D. & Clark, G. J. The RASSF1A tumor suppressor. J Cell Sci \n                           120, 3163\u20133172 (2007).","journal-title":"J Cell Sci"},{"key":"3143_CR25","first-page":"3635","volume":"9","author":"SM Dong","year":"2003","unstructured":"Dong, S. M. et al. Epigenetic inactivation of RASSF1A in head and neck cancer. Clin Cancer Res \n                           9, 3635\u20133640 (2003).","journal-title":"Clin Cancer Res"},{"key":"3143_CR26","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1093\/jnci\/93.9.691","volume":"93","author":"DG Burbee","year":"2001","unstructured":"Burbee, D. G. et al. Epigenetic inactivation of RASSF1A in lung and breast cancers and malignant phenotype suppression. Journal of the National Cancer Institute \n                           93, 691\u2013699 (2001).","journal-title":"Journal of the National Cancer Institute"},{"key":"3143_CR27","doi-asserted-by":"publisher","first-page":"1509","DOI":"10.1038\/sj.onc.1204175","volume":"20","author":"A Agathanggelou","year":"2001","unstructured":"Agathanggelou, A. et al. Methylation associated inactivation of RASSF1A from region 3p21.3 in lung, breast and ovarian tumours. Oncogene \n                           20, 1509\u20131518 (2001).","journal-title":"Oncogene"},{"key":"3143_CR28","doi-asserted-by":"publisher","first-page":"2551","DOI":"10.1158\/1078-0432.CCR-07-1867","volume":"14","author":"J Geli","year":"2008","unstructured":"Geli, J. et al. Global and regional CpG methylation in pheochromocytomas and abdominal paragangliomas: association to malignant behavior. Clin Cancer Res \n                           14, 2551\u20132559 (2008).","journal-title":"Clin Cancer Res"},{"key":"3143_CR29","first-page":"861","volume":"33","author":"JJ Lee","year":"2008","unstructured":"Lee, J. J. et al. Gene-specific promoter hypermethylation without global hypomethylation in follicular thyroid cancer. International journal of oncology \n                           33, 861\u2013869 (2008).","journal-title":"International journal of oncology"},{"key":"3143_CR30","doi-asserted-by":"publisher","first-page":"3157","DOI":"10.1128\/MCB.22.9.3157-3173.2002","volume":"22","author":"M Curradi","year":"2002","unstructured":"Curradi, M., Izzo, A., Badaracco, G. & Landsberger, N. Molecular mechanisms of gene silencing mediated by DNA methylation. Mol Cell Biol \n                           22, 3157\u20133173 (2002).","journal-title":"Mol Cell Biol"},{"key":"3143_CR31","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1006\/meth.2001.1262","volume":"25","author":"KJ Livak","year":"2001","unstructured":"Livak, K. J. & Schmittgen, T. D. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods \n                           25, 402\u2013408 (2001).","journal-title":"Methods"},{"key":"3143_CR32","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1186\/1471-2105-11-230","volume":"11","author":"C Rohde","year":"2010","unstructured":"Rohde, C., Zhang, Y., Reinhardt, R. & Jeltsch, A. BISMA\u2013fast and accurate bisulfite sequencing data analysis of individual clones from unique and repetitive sequences. BMC bioinformatics \n                           11, 230 (2010).","journal-title":"BMC bioinformatics"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-017-03143-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-017-03143-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-017-03143-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,23]],"date-time":"2022-12-23T05:10:26Z","timestamp":1671772226000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-017-03143-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,6,9]]},"references-count":32,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2017,12]]}},"alternative-id":["3143"],"URL":"https:\/\/doi.org\/10.1038\/s41598-017-03143-8","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,6,9]]},"assertion":[{"value":"1 February 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 April 2017","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 June 2017","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare that they have no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}}],"article-number":"3123"}}